Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

GlaxoSmithKline482 enrolled

Overview

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

482

Conditions

Nausea and Vomiting, Postoperative

Interventions

GW679769 (casopitant)DRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * History of PONV and/or motion sickness. * Have not smoked for the last 6 months. * Having certain types of abdominal, breast or shoulder surgeries. Exclusion criteria: * Pregnant or breastfeeding. * Taking certain medications. * Have certain pre-existing medical conditions.

Locations (58)

Outcomes

Primary Outcomes

Rates of vomiting and retching

Time frame: after surgery

Secondary Outcomes

Rates of nausea. Blood test results.

Time frame: after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

GSK Investigational Site

Montgomery, Alabama, United States

GSK Investigational Site

Sheffield, Alabama, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Boynton Beach, Florida, United States

GSK Investigational Site

Jacksonville, Florida, United States

GSK Investigational Site

Melbourne, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Naples, Florida, United States

GSK Investigational Site

Pensacola, Florida, United States

...and 48 more locations